Life Biosciences Appoints Veteran Biotech Leader David Guyer to Board as Company Prepares for First Human Trials
核心洞察
Life Biosciences (搜索) has appointed industry veteran David Guyer (搜索), M.D., to its Board of Directors as the company prepares to initiate human trials for its lead program ER-100 in the first quarter of 2026.
Dr. Guyer brings over 30 years of drug development experience, including developing the first anti-VEGF (搜索) drug for macular degeneration (搜索) and overseeing the sale of EyeBio (搜索) to Merck in July 2024.
The company's proprietary Partial Epigenetic Reprogramming platform utilizes three transcription factors to restore older cells to a younger state, targeting age-related diseases at the epigenetic level.
Life Biosciences (搜索) announced the appointment of David Guyer (搜索), M.D., to its Board of Directors, effective November 1, 2025, as the biotechnology company prepares to advance its cellular rejuvenation therapy into human trials. The appointment comes as Life Bio prepares to initiate clinical testing of its lead program ER-100 in the first quarter of 2026, marking a critical milestone for the company's partial epigenetic reprogramming platform.
Strategic Leadership Addition
Dr. Guyer brings extensive biotechnology leadership experience to Life Bio's board, with over 30 years in drug development as both a chief executive officer and venture capitalist. Currently serving as cofounder, president, and chief executive officer of EyeBio (搜索), a subsidiary of Merck & Co., Inc., Dr. Guyer has demonstrated a strong track record in developing and commercializing breakthrough therapies.
"We are delighted to welcome David to our Board of Directors. David has served as an advisor to Life Bio for a number of years and, as a Board member, will bring us a rare depth of scientific and operational rigor, governance expertise, and regulatory experience," said Jerry McLaughlin, Chief Executive Officer of Life Bio.
Proven Track Record in Ophthalmology
Dr. Guyer's expertise in ophthalmology aligns strategically with Life Bio's current focus on optic neuropathies (搜索). He developed and commercialized the first anti-VEGF (搜索) (vascular endothelial growth factor) drug for macular degeneration (搜索) as cofounder and CEO of Eyetech Pharmaceuticals. His experience includes taking two companies public, managing numerous mergers and acquisitions, and serving on over 25 company boards.
In July 2024, Dr. Guyer oversaw the sale of EyeBio (搜索) to Merck & Co., Inc., demonstrating his ability to create significant shareholder value. He previously served as professor and chairman of the Department of Ophthalmology at New York University School of Medicine and is currently a venture partner at SV Health Investors (搜索).
Innovative Therapeutic Platform
Life Bio's proprietary Partial Epigenetic Reprogramming (PER) platform utilizes three transcription factors—Oct4 (搜索), Sox2 (搜索), and Klf4 (搜索)—to restore older and damaged cells to a younger and healthier state. This approach targets aging at the epigenetic level, offering potential to address multiple age-related diseases across various organ systems.
"Life Bio's innovative approach to reversing age-related disease is extremely compelling," said Dr. Guyer. "Having been involved with Life Bio for a number of years, I have been impressed with the leadership team's focused development of the company's partial epigenetic reprogramming platform."
Clinical Development Timeline
The company's lead program, ER-100, is being developed for optic neuropathies (搜索), including glaucoma (搜索) and non-arteritic anterior ischemic optic neuropathy (搜索) (NAION). McLaughlin emphasized the strategic timing of Dr. Guyer's appointment, stating his "insight into translational development and value creation will be invaluable as we scale Life Bio's platform and pipeline" and "take ER-100 into human trials in the first quarter of 2026."
Board Transition
Concurrent with Dr. Guyer's appointment, Bracken Darrell stepped down from the Board of Directors, effective November 1, 2025. Darrell had served on the board since 2018, contributing leadership experience and strategic insight during his tenure.
"I am so excited to welcome David to our Board. On behalf of the Board and management team, I want to thank Bracken for his invaluable service, guidance, and commitment to Life Bio," said David Sinclair, Ph.D., Life Bio's Co-founder and Board Chair.
Dr. Guyer expressed enthusiasm about expanding the platform's applications beyond ophthalmology, noting that while his background as an ophthalmologist aligns with Life Bio's ophthalmic indications, he looks forward to "bringing my experience as an executive and board member to broadening this innovative platform across multiple organ systems."